Bradley Monk shares key insights and breakthroughs in gynaecologic oncology from ESGO 2025, shaping cancer care's future.

AbbVie today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab soravtansine-gynx) in women with folate receptor alpha ...

Longevity research has propelled the scientific community to concentrate on interventions that do more than simply add years ...

All humans have the BRCA genes (BRCA1 and BRCA2). You inherit one from each of your parents, and if one parent has a mutation ...

Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an internally discovered USP1 inhibitor, for the treatment of advanced solid tumors. LAE120 ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor ... committed to bringing life-changing medicines ...

Eikon Therapeutics, the brainchild of Roger Perlmutter, has raised a total of $1.1 billion since it launched in 2019.

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.

Ieq Capital LLC purchased a new stake in Nuvation Bio Inc. (NYSE:NUVB – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 36,993 shares of ...

ReShape Lifesciences saw a surge in retail discussion as traders speculated on the potential approval of its proposed reverse ...